Martin Kornacker

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis
    M Kornacker
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 94:513-9. 2001
  2. ncbi Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases
    M Kornacker
    Department of Medicine V, University of Heidelberg, Hospitalstr 3, 69115 Heidelberg, Germany
    Ann Hematol 81:103-5. 2002
  3. ncbi Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma
    Martin Kornacker
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 119:1377-82. 2006
  4. ncbi Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases
    M Kornacker
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Eur J Haematol 74:250-3. 2005
  5. ncbi Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells
    Freddy Tita-Nwa
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Cancer Immunol Immunother 56:1911-20. 2007
  6. ncbi Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells
    Mathias Witzens-Harig
    Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany
    Stem Cells 25:228-35. 2007
  7. ncbi Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma
    Manfred Hensel
    Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Clin Lymphoma Myeloma 6:131-5. 2005
  8. ncbi Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia
    Manfred Hensel
    Department of Internal Medicine V, University of Heidelberg, Hospitalstrasse 3, D 69115 Heidelberg, Germany
    Br J Haematol 122:600-6. 2003
  9. ncbi Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma
    Jana Schlenzka
    University Hospital for Internal Medicine, Department of Hematology Oncology, Heidelberg University Medical School, Heidelberg, Germany
    Anticancer Drugs 15:915-9. 2004
  10. ncbi Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support
    Manfred Hensel
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Stem Cells 20:32-40. 2002

Collaborators

Detail Information

Publications16

  1. ncbi Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis
    M Kornacker
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 94:513-9. 2001
    ....
  2. ncbi Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases
    M Kornacker
    Department of Medicine V, University of Heidelberg, Hospitalstr 3, 69115 Heidelberg, Germany
    Ann Hematol 81:103-5. 2002
    ..When a suspected relapse of lymphoma presents with signs and symptoms compatible with sarcoidosis, this rare immunologic disorder has to be ruled out by careful clinical and histopathologic analysis to prevent mistreatment...
  3. ncbi Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma
    Martin Kornacker
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 119:1377-82. 2006
    ..In addition to their direct cytotoxic effect, CIK cells secrete IFN-gamma that modulates the expression of adhesion molecules on CLL cells, and this enhances apoptosis induction by cytotoxic effector cells...
  4. ncbi Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases
    M Kornacker
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Eur J Haematol 74:250-3. 2005
    ..All three patients had high dose Melphalan therapy with autologous stem cell support preceding the allogeneic transplantation for several weeks, which may have contributed to endothelial damage and subsequent development of TMA...
  5. ncbi Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells
    Freddy Tita-Nwa
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Cancer Immunol Immunother 56:1911-20. 2007
    ..The in vitro studies outlined here support the experimental use of bsAb HD37xT5.16 in preclinical in vivo models for evaluation of its safety and efficacy profile...
  6. ncbi Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells
    Mathias Witzens-Harig
    Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany
    Stem Cells 25:228-35. 2007
    ....
  7. ncbi Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma
    Manfred Hensel
    Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Clin Lymphoma Myeloma 6:131-5. 2005
    ..Pentostatin has demonstrated significant activity as a single agent in patients with low-grade B-cell and T-cell lymphomas and is less myelosuppressive than other purine analogues...
  8. ncbi Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia
    Manfred Hensel
    Department of Internal Medicine V, University of Heidelberg, Hospitalstrasse 3, D 69115 Heidelberg, Germany
    Br J Haematol 122:600-6. 2003
    ..Preferably, prophylactic strategies should be evaluated in patients defined by these parameters...
  9. ncbi Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma
    Jana Schlenzka
    University Hospital for Internal Medicine, Department of Hematology Oncology, Heidelberg University Medical School, Heidelberg, Germany
    Anticancer Drugs 15:915-9. 2004
    ..c. tumor. These results suggest that a combination treatment with recombinant diabodies and angiogenesis inhibition represents a useful approach in cancer therapy...
  10. ncbi Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support
    Manfred Hensel
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Stem Cells 20:32-40. 2002
    ..Our observation might indicate a favorable effect of HDCT in MBC patients with overexpression of Her2/neu who might have a worse prognosis when treated with conventional chemotherapy...
  11. doi Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up
    M Kornacker
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Ann Oncol 20:722-8. 2009
    ..Pattern and outcome of disease recurrence after autologous stem-cell transplantation (autoSCT) for follicular lymphoma (FL) is not well known...
  12. ncbi The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab
    M Kornacker
    Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
    Cytotherapy 8:13-23. 2006
    ..While bsAb may improve T-cell mediated anti-tumor activity, little is known about the fate of effector cells upon redirection to tumor targets using a bsAb...
  13. doi Commercial LightCycler-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma
    M Kornacker
    Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Ann Hematol 88:43-50. 2009
    ..The data shown here demonstrate a lower sensitivity of LightCycler vs. nested PCR for detection of t(14;18). The usefulness of nested PCR for t(14;18) for risk stratification after primary therapy has to be validated in larger trials...
  14. ncbi Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells
    Michael R Verneris
    Department of Pediatrics, Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 11:4561-70. 2005
    ..To identify novel treatments for pediatric solid tumors and/or for malignancies with low-level Her2/neu expression...
  15. ncbi Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3
    Christian Scheffold
    Division of Bone Marrow Transplantation, Stanford University School of Medicine, California 94305, USA
    Cancer Res 62:5785-91. 2002
    ..These studies have demonstrated that CD8+ NKT cells can be successfully redirected to tumor cells using bispecific antibodies and offer a promising strategy for adoptive immunotherapy of neoplastic diseases...
  16. ncbi Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro
    Philipp Niemeyer
    Department of Orthopaedic Surgery and Traumatology, University of Freiburg, Germany
    Tissue Eng 13:111-21. 2007
    ..Our results suggest that allogenic transplantation of BMSCs and ASCs would be possible, for example, in the context of tissue engineering...